<DOC>
	<DOCNO>NCT02386423</DOCNO>
	<brief_summary>The purpose study determine safety efficacy RESTIFFIC™ , foot wrap produce adjustable targeted pressure specific muscle foot , reduce symptom moderate severe primary Restless Legs Syndrome .</brief_summary>
	<brief_title>RESTIFFIC™ Foot Wrap Reduces Moderate Severe Restless Leg Syndrome</brief_title>
	<detailed_description>Restless legs syndrome ( RLS ) , Willis-Ekbom Disease , neurologic disorder cause unpleasant sensation urge move leg person rest . The sensation relieve movement . Loss sleep associate RLS cause extreme fatigue , affect concentration , may produce anxiety depression , result poor quality life . Prevalence general population 5 % 10 % . In approximately 3 % , symptom severe treatment sought . Potent drug , opioids , central nervous system depressant , anticonvulsant , dopamine agonist use ease symptom , several side effect . Anecdotal evidence suggest pressure specific foot muscle decrease symptom moderate severe primary restless legs syndrome . In RESTIFFIC™ study , patient serve negative control , wear RESTIFFIC™ device intermittently , complete survey relate RLS throughout study . Physicians also complete survey relate quality life . Meta-analysis use compare RESTIFFIC™ historic report ropinirole placebo pill . Demographics , disease severity , inclusion/exclusion criterion , assessment tool similar among study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<criteria>Otherwise healthy adult age 18 75 year diagnose moderate severe RLS recruit Erie surround region . The patient examine physician screen use medical history , International RLS study group diagnostic criterion , International RLS Study ( IRLSS ) Rating Scale . To include , patient : ( 1 ) total score 15 great International RLS Rating Scale ; ( 2 ) evening nighttime symptom sleep impairment ( selfreport ) due RLS ; ( 3 ) RLS least six month symptom least two three time per week . The potential least 12 many 42 episode RLS treatment period . The patient exclude he/she serious medical condition condition may present safety concern may impact efficacy assessment , eg , take drug like antidepressant know affect RLS . Medical condition include , limit : claudication , nerve problem , fragile , thin skin , impair wound healing ; poor circulation , injury foot leg , movement problem , inability sit still remain motionless , involuntary movement similar tic , sleep disorder , parasomnias involve abnormal movement , narcolepsy , obstructive sleep apnea , nighttime discomfort due RLS , secondary RLS , Parkinson 's Disease . Patients drug treatment RLS must discontinue treatment least 30 day . ( Note : None patient drug treatment RLS . ) Through history physical examination , physician distinguish RLS disorder periodic Limb Movement Disorder ( footnote 5 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>RLS</keyword>
	<keyword>Willis-Ekbom</keyword>
</DOC>